Southern Acids (M) Berhad 대차 대조표 상태

재무 상태 기준 확인 5/6

Southern Acids (M) Berhad 의 총 주주 지분은 MYR870.9M 이고 총 부채는 MYR20.6M, 이는 부채 대 자기자본 비율을 2.4% 로 가져옵니다. 총자산과 총부채는 각각 MYR1.0B 및 MYR144.5M 입니다. Southern Acids (M) Berhad 의 EBIT는 MYR35.3M 이며 이자보상배율은 41.2 입니다. MYR381.4M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

2.4%

부채 비율

RM 20.60m

부채

이자 보상 비율	41.2x
현금	RM 381.40m
주식	RM 870.92m
총 부채	RM 144.53m
총 자산	RM 1.02b

최근 재무 상태 업데이트

업데이트 없음

Recent updates

Southern Acids (M) Berhad's (KLSE:SAB) Soft Earnings Are Actually Better Than They Appear

Mar 03

If You Like EPS Growth Then Check Out Southern Acids (M) Berhad (KLSE:SAB) Before It's Too Late

May 27

The Returns At Southern Acids (M) Berhad (KLSE:SAB) Aren't Growing

Apr 19

Are Strong Financial Prospects The Force That Is Driving The Momentum In Southern Acids (M) Berhad's KLSE:SAB) Stock?

Feb 24

Returns On Capital At Southern Acids (M) Berhad (KLSE:SAB) Paint An Interesting Picture

Jan 13

What Can We Learn About Southern Acids (M) Berhad's (KLSE:SAB) CEO Compensation?

Dec 15

Southern Acids (M) Berhad (KLSE:SAB) Share Prices Have Dropped 14% In The Last Three Years

Nov 24

재무 상태 분석

단기부채: SAB 의 단기 자산 ( MYR614.0M )이 단기 부채( MYR109.5M ).

장기 부채: SAB 의 단기 자산( MYR614.0M )이 장기 부채( MYR35.0M ).

부채 대 자본 내역 및 분석

부채 수준: SAB 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: SAB 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 2.4% 로 증가했습니다.

부채 범위: SAB 의 부채는 영업 현금 흐름 ( 110.5% )에 의해 잘 충당되었습니다.

이자 보장: SAB 의 부채에 대한 이자 지급은 EBIT( 41.2 x 적용 범위)로 잘 충당됩니다.

Southern Acids (M) Berhad 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

Recent updates

New minor risk - Market cap size

Upcoming dividend of RM0.05 per share

New major risk - Revenue and earnings growth

Full year 2024 earnings released: EPS: RM0.10 (vs RM0.24 in FY 2023)

Southern Acids (M) Berhad, Annual General Meeting, Aug 26, 2024

New minor risk - Market cap size

Full year 2024 earnings released: EPS: RM0.10 (vs RM0.24 in FY 2023)

Southern Acids (M) Berhad Announces Redesignation of Chung Kin Mun from Independent Director to Non Independent and Non Executive Director

Third quarter 2024 earnings released: EPS: RM0.033 (vs RM0.12 in 3Q 2023)

Southern Acids (M) Berhad Announces Redesignation of Stephen Wan Yeng Leong from Member of Audit Committee to Independent and Non Executive Chairman of Audit Committee

Southern Acids (M) Berhad (KLSE:SAB) entered into agreement to acquire remaining 10% stake in Firstview Development Sdn Bhd from Low Mong Hua Sdn Berhad for RM 23.5 million.

Second quarter 2024 earnings released: RM0.039 loss per share (vs RM0.081 profit in 2Q 2023)

Upcoming dividend of RM0.05 per share at 1.5% yield

Southern Acids (M) Berhad Announces Appointment of Deborah Deb-Bie Choa as Independent and Non Executive Director

First quarter 2024 earnings released: EPS: RM0.067 (vs RM0.11 in 1Q 2023)

New minor risk - Market cap size

Full year 2023 earnings released: EPS: RM0.24 (vs RM0.69 in FY 2022)

Southern Acids (M) Berhad, Annual General Meeting, Aug 30, 2023

Southern Acids (M) Berhad Announces Cessation of Office of Madam Leong So Seh as Member of Nomination and Remuneration Committee

Full year 2023 earnings released: EPS: RM0.24 (vs RM0.69 in FY 2022)

Outhern Acids (M) Berhad Recommends Single Tier Final Dividend in Respect of the Financial Year Ended 31 March 2023

Southern Acids (M) Berhad's (KLSE:SAB) Soft Earnings Are Actually Better Than They Appear

Third quarter 2023 earnings released: EPS: RM0.12 (vs RM0.20 in 3Q 2022)

Second quarter 2023 earnings released: EPS: RM0.082 (vs RM0.13 in 2Q 2022)

Price target decreased to RM3.40

Insufficient new directors

Upcoming dividend of RM0.05 per share

Full year 2022 earnings released: EPS: RM0.69 (vs RM0.27 in FY 2021)

Southern Acids (M) Berhad Announces Final Dividend, Payable on 28 Nov. 2022

Southern Acids (M) Berhad Recommends Single Tier Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to RM3.40

Insufficient new directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

First quarter 2022 earnings released: EPS RM0.17 (vs RM0.13 in 1Q 2021)

Upcoming dividend of RM0.05 per share

Full year 2021 earnings released: EPS RM0.27 (vs RM0.23 in FY 2020)

Price target decreased to RM3.40

Full year 2021 earnings released: EPS RM0.27 (vs RM0.23 in FY 2020)

If You Like EPS Growth Then Check Out Southern Acids (M) Berhad (KLSE:SAB) Before It's Too Late

Southern Acids (M) Berhad Recommends Final Dividend for the Year Ended March 31, 2021

The Returns At Southern Acids (M) Berhad (KLSE:SAB) Aren't Growing

Third quarter 2021 earnings released: EPS RM0.041 (vs RM0.076 in 3Q 2020)

Are Strong Financial Prospects The Force That Is Driving The Momentum In Southern Acids (M) Berhad's KLSE:SAB) Stock?

Returns On Capital At Southern Acids (M) Berhad (KLSE:SAB) Paint An Interesting Picture

What Can We Learn About Southern Acids (M) Berhad's (KLSE:SAB) CEO Compensation?

New 90-day high: RM3.88

Southern Acids (M) Berhad Announces Appointment of Tan Sri Datuk Seri Panglima Sulong Bin Matjeraie as Independent and Non Executive Ember of Audit Committee

Second quarter 2021 earnings released: EPS RM0.06

Southern Acids (M) Berhad (KLSE:SAB) Share Prices Have Dropped 14% In The Last Three Years

New 90-day high: RM3.80

Southern Acids (M) Berhad Announces the Resignation of Encik Teo Leng as Independent and Non Executive Member of Audit Committee

New 90-day high: RM3.72

Upcoming Dividend of RM0.05 Per Share

First quarter earnings released

New 90-day high - RM3.68

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기